Ammonia is putatively the major toxin associated with hepatic encephalopathy (HE), a neuropsychiatric manifestation that results in cognitive impairment, poor concentration and psychomotor alterations. The hippocampus, a brain region involved in cognitive impairment and depressive behavior, has been studied less than neocortical regions. Herein, we investigated hippocampal astrocyte parameters in a hyperammonemic model without hepatic lesion and in acute hippocampal slices exposed to ammonia. We also measured hippocampal BDNF, a neurotrophin commonly related to synaptic plasticity and cognitive deficit, and peripheral S100B protein, used as a marker for brain damage. Hyperammonemia directly impaired astrocyte function, inducing a decrease in glutamate uptake and in the activity of glutamine synthetase, in turn altering the glutamine-glutamate cycle, glutamatergic neurotransmission and ammonia detoxification itself. Hippocampal BDNF was reduced in hyperammonemic rats via a mechanism that may involve astrocyte production, since the same effect was observed in astrocytecultures exposed to ammonia. Ammonia induced a significant increase in S100B secretion in cultured astrocytes; however, no significant changes were observed in the serum or in cerebrospinal fluid. Data demonstrating hippocampal vulnerability to ammonia toxicity, particularly due to reduced glutamate uptake activity and BDNF content, contribute to our understanding of the neuropsychiatric alterations in HE.
Introduction
Hyperammonemia is a multifactorial condition resulting from liver commitment or other diseases, such as inborn errors of urea synthesis (Felipo and Butterworth, 2002; Hertz et al., 2016) . It is well known that 90% of hepatic disorders are accompanied by an elevationin brain ammonia. Such patients display similar clinical, biochemical and physiological dysfunctions, such as respiratory alkalosis, increases in plasma and brain glutamine, astrocyte swelling and cerebral edema. In some cases, these patients manifest neuropsychiatric symptoms, referred to hepatic encephalopathy (Aldridge et al., 2015; Brusilow et al., 2010) .
Astrocytesare the major cells affected by hyperammonemia in the central nervous system (CNS), partially due to their proximity to the blood vessels (Norenberg et al., 2009) . Clear morphological changes occur in astrocytes following acute ammonia exposure, such as extensive swelling, causing a drastic cerebral edema (Seyan et al., 2010) . Recently, astrocytes were found to play an important role in hyperammonemia-induced neuroinflammation and increase senescence-associated genes (Görg et al., 2015; Hernández-Rabaza et al., 2016) . Furthermore, astrocytes express glutamine synthetase (GS), the enzyme responsible for the detoxification of ammonia (Brusilow et al., 2010) , and play an essential role in the glutamine-glutamate cycle. These cells are responsible for the clearance of glutamate from the synaptic cleft, preventing excitotoxicity (Hertz and Zielke, 2004; Magistretti and Pellerin, 1999) . Furthermore, this function is interconnected with GS activity and glutathione synthesis (GSH), since glutamate is a substrate for both reactions (Matés et al., 2002; Trabelsi et al., 2017; Wegrzynowicz et al., 2007) . Therefore, glutamate uptake commitment may reduce the intracellular levels of this amino acid (Butterworth, 2002) , which may in turn interfere in the GS activity available for the detoxification of ammonia (Suarez et al., 2002) , as well as reduce the production of glutathione (Dringen, 2000) . Reduced GSH may increase reactive oxidative species levels, leading to oxidative damage to the glutamate transporters, and contributing to glutamate uptake impairment.
However, the effect of hyperammonemia in classical astrocytic function is frequently contradictory in the literature, probably due to different brain regions analyzed (Cauli et al., 2007) . For example, hyperammonemic toxicity is not associated with alterations in GS activity in total brain or brain stem cells (Butterworth et al., 1988; Cooper et al., 1985) , but reduces GS activity in the cerebral cortex of shunted rats and HE patients (Butterworth et al., 1988; Lavoie et al., 1987) . GSH content is up regulated in the cerebellum of ammoniaintoxicated rats (Singh et al., 2008) , is reduced in total brain extracts and the cerebral cortex of hyperamonemic rats and in an acute model of HE (Kosenko et al., 1997; Mustafa et al., 2013; Ruszkiewicz et al., 2013) , but unchanged in the striatum of thiocetamide intoxicated rats (Ruszkiewicz et al., 2013) . In fact, ammonia has been found to be differentially metabolized depending on the brain region, particularly with regard to the glutamatergic and antioxidant system (Hiba et al., 2016; Kosenko et al., 2014a Kosenko et al., , 2014b . Most studies have been carried out in total brain extracts and in the cerebral cortex; however, little is known about its effects on the hippocampus (Girard and Butterworth, 1992; Kosenko et al., 1999) , which is an area that has been associated to depression (Nestler et al., 2002) and cognitive deficit (Ahmed et al., 2015) and is responsible for amnestic symptoms and learning deficits in HE patients (Arias et al., 2015; Ding et al., 2013; Hernández-Rabaza et al., 2016) . S100B and BDNF have been proposed as biomarkers for neurocognitive dysfunction (Chong et al., 2016; Galvez-Contreras et al., 2016) . S100B is expressed mainly in astrocytes and isreported to be increased in the serum of patients with fulminant hepatitis, in animal models of HE (Isobe-Harima et al., 2008) and in the serum of patients with HE caused by cirrhosis (Saleh et al., 2007; Wiltfang et al., 1999) . However, little is known about the secretion of this protein in hyperammonemic conditions. Similarly, BDNF is an important neurotrophic factor that is involved in synaptic plasticity and modulation of long and short term memory, amongst other functions, and has also been associated with depression and neurocognitive deficits (Alonso et al., 2002; Binder and Scharfman, 2004; Yamada and Nabeshima, 2003) . Despite its involvement in these parameters, to our knowledge, BDNF has not been analyzed in any hyperammonemic condition.
Considering the heterogeneity of data in the literature, depending on brain region, the lack of information regarding astrocytic function in the hippocampus, and the involvement of BDNF in ammonia toxicity, we herein investigated the direct effect of toxic ammonia levels on astrocytic parameters of the rat hippocampus, specifically on glutamate uptake, GS activity, S100B and GFAP, and other parameters related to astrocytic activity, such as GSH and BDNF. To this end, we employed in vivo and in vitro approaches; hyperammonemia was induced in rats via an intraperitoneal injection of urease, which has been widely used to evaluate the effects of high levels of ammonia on brain function (Diemer and Laursen, 1977; Viegas et al., 2012) , without inducing hepatic damage. Additionally, acute brain slices were exposed to ammonia and astrocyte cultures were also used to further investigate S100B and BDNF signaling.
Experimental procedures

Materials
Anti-S100B antibody (SH-B1), anti-GFAP antibody, anti-actin, methylthiazolyldiphenyl-tetrazolium bromide (MTT), neutral red, glutathione, phthaldialdehyde and urease were purchased fromSigma [St. Louis, USA]. Polyclonal anti-S100B and anti-rabbit peroxidase were purchased from DAKO [São Paulo, Brazil] and GE [Little Chalfont, United Kingdom], respectively. Anti-glutamine synthetaseand anti-goat IgG-R were bought from Santa Cruz. L-[2,3-3 H] Glutamate was obtained from Amersham International (UK).
Animals
Thirty-day old female Wistar rats were obtained from the Central Animal House of the Department of Biochemistry, ICBS, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. The animals were maintained on a 12:12 h light/dark cycle (lights on 07.00-19.00 h) in an air conditioned room maintained at constant temperature (22 AE 1 C), with free access to water and a 20% (w/w) protein commercial chow (SUPRA, Porto Alegre, RS, Brazil). The experimental protocol was approved by the Ethics Committee for animal research of the Federal University of Rio Grande do Sul, Porto Alegre, Brazil and followed the "Principles of Laboratory Animal Care (NIH publication 85-23, revised 1996) . All efforts were made to minimize the number of animals used and their suffering. For cell culture preparations, 2-day-old Wistar rats were obtained from the Central Animal House of the Department of Biochemistry, ICBS, Universidade Federal do Rio Grande do Sul, RS, Brazil.
Urease administration
An animal model of hyperammonemia was used, based on urease administration (Diemer and Laursen, 1977) . Sustained hyperammonemia was induced by daily intraperitoneal injection of a urease solution (33 U/kg body weight) for 4 days from the 30th until the 34th day of postnatal life. The chosen dose of urease did not cause hyperexcitability, convulsions or death, as described in previous publications (Diemer and Laursen, 1977) . Urease was dissolved in 0.2 M sodium saline buffer, pH 7.0. Control rats received the same volume of saline. Twenty-four hours after the last injection, rats were anesthetized with ketamine/xylazine (75and 10 mg/kg, respectively, i.p.) and placed in a stereotaxic apparatus for cisterna magna puncture. Blood samples were obtained by intracardiac puncture and were incubated at room temperature (25 C) for 5 min and then centrifuged at 3200 rpm for 5 min to obtain serum samples. After decapitation, brains were removed and then placed in cold physiological saline medium. The hippocampi were dissected out and cut into 0.3-mm slices using a McIlwain Tissue Chopper for posterior analysis, as described below.
Serum ammonia determination
Ammonia levels were measured in controls and urease-treated rats using a commercial kit (Sigma, St. Louis, MO), immediately after serum was obtained. Ammonia concentration was calculated according to the manufacturer's protocol.
ALT and AST activity assays
The serum enzymes of controls and urease-treated rats were assayed using diagnostic kits provided by BioTécnica -Biotecnologia Avançada (Varginha, Brasil) and the procedure was followed as described by the manufacturer's protocol.
GFAP measurement
The ELISA for GFAP was carried out, as previously described (Tramontina et al., 2007) , in homogenates of hippocampal slices, by coating microtiter plates with 100 mL of diluted samples or standard human GFAP (from Calbiochem) ranging from 0.1 to 5 ng for 24 h at 4 C. Incubation with a rabbit polyclonal anti-GFAP (dilution in 0.5% M-TBS) for 1 h was followed by incubation with a secondary antibody conjugated with peroxidase for 1 h, at room temperature. A colorimetric reaction with o-phenylenediamine was measured at 492 nm.
Hippocampal slices
Hippcampal slices preparation was done as previously described (Nardin et al., 2009 ). Briefly, thirty-day old Wistar rats, without any previously treatment, were killed by decapitation. Hippocampi were quickly dissected out and transverse sections (300 mm) were rapidly obtained using a McIlwain tissue chopper.
One slice was placed into each well of a 24-well culture plate. Slices were incubated in oxygenated physiological medium (containing, in mM; 120 NaCl, 2 KCl, 1 CaCl 2 , 1 MgSO 4 , 25 HEPES, 1 KH 2 PO 4 and 10 glucose, pH 7.4) at room temperature, and the medium was changed every 15 min with fresh medium. Following a 120-min equilibration period, slices were incubated with or without NH 4 Cl at concentrations ranging from 0.1 to 10 mM, for 60 min at 30 C on a warm plate. Subsequently, media or slices were collected for posterior analysis.
MTT reduction assay
Hippocampal slices were incubated with 50 mg/mL methylthiazolyldiphenyl-tetrazolium bromide (MTT) during the last 30 min of ammonia exposure at 30 C. Afterwards, the media was removed and MTT crystals were dissolved in DMSO. Absorbance values were measured at 560 and 650 nm. The reduction of MTT was calculated as (abs at 560 nm) À (abs at 650 nm) and expressed as a percentage of basal.
Neutral red uptake
Neutral red incorporation was carried out as previously described . Hippocampal slices were incubated with 50 mg/mL neutral red (NR) during the last 30 min of ammonia exposure at 30 C. Subsequently, slices were rinsed twice with phosphate buffer for 5 min and NR dye taken up by viable cells was extracted with 500 mL acetic acid/ethanol/water (1/50/49) solution. Absorbance values were measured at 560 nm.
Lactate dehydrogenase (LDH) activity assay
The lactate dehydrogenase assay was carried out in 50 mL of the supernatant of treated slices, using a commercial colorimetric assay from Doles (Goiânia, Brazil).
2.11. S100B measurement S100B was measured by ELISA, as previously described . Briefly, 50 mL of sample (previously homogenized and diluted) plus 50 mL of Tris buffer 50 mM were incubated for 2 h on a microtiter plate previously coated overnight with monoclonal anti-S100B and blocked for 1 h with 2% albumin from chicken egg. Polyclonal anti-S100 was incubated for 30 min and then peroxidase-conjugated anti-rabbit antibody was added for a further 30 min. Te microtiter plate was rinsed tree times between each step with a wash solution. O-phenylenediamine was added for30 min and the colorimetric reaction and was determined at 492 nm. The standard S100B curve ranged from 0.002 to 1 ng/mL for samples from extracellular medium (ex vivo treatment) and ranged from 0.02 to 10 ng/mL for samples from tissue (in vivo treatment).
Glutamate uptake assay
Glutamate uptake was measured, as previously described (Gottfried et al., 2002) with some modifications (Thomazi et al., 2004) H] glutamate. The reaction was stopped after 5 min by removal of the medium and rinsing the slices three times with icecold HBSS. The slices were then lysed in 0.5 M NaOH. Radioactivity was measured in a scintillation counter. Sodium-independent uptake was determined using a solution containing N-methyl-Dglucamine instead of NaCl. Glutamate uptake was obtained by subtracting the non-specific uptake (sodium-independent uptake) from the total uptake. Results (nmol/mg protein/min) were expressed as a percentage of the control.
GSH
Glutathione content was determined as previously described (Browne and Armstrong, 1998) . Briefly, hippocampal slices were homogenized in sodium phosphate buffer (0.1 M, pH 8.0) containing 5 mM EDTA and protein was precipitated with 1.7% meta-phosphoric acid. Supernatant was assayed with 1 mg/mL ophthaldialdehyde at room temperature for 15 min. Fluorescence was measured using excitation and emission wavelengths of 350 and 420 nm, respectively. A calibration curve was performed with standard glutathione solutions (0-500 mM).
GS activity
The enzymatic activity of glutamine synthetase was determined using the procedures described previously (Minet et al., 1997) with modifications. Briefly, samples were homogenized in 50 mM imidazole. Homogenates were incubated with (mM): (50 imidazole, 50 hydroxylamine, 100 L-glutamine, 25 sodium arsenate dibasic heptahydrate, 0.2 ADP, 2 manganese chloride, pH 6.2) and incubated for 15 min at 37 C. The reaction was stopped by the addition of 0.2 mL of 0.37 M FeCl 3 , 200 mM trichloroacetic acid, and 0.67 M HCl. After centrifugation, the absorbance of the supernatant was measured at 540 nm and compared to the absorbance generated by standard quantities of g-glutamylhydroxamate acid (Sigma) added to ferric chloride reagent. Glutamine synthetase activity was expressed as mmol/h/mg prot.
GS immunocontent determination
The hippocampi of controls and urease-treated rats were homogenated and transferred to Eppendorf tubes. Equal amounts (30 mg) of proteins from each sample were boiled in sample buffer (0.0625 M Tris-HCl, pH 6.8, 2% (w/v) SDS, 5% (w/v) b-mercaptoethanol, 10% (v/v) glycerol, 0.002% (w/v) bromphenol blue) and electrophoresed in a 12% (w/v) SDS-polyacrylamide gel. The separated proteins were blotted onto a nitrocellulose membrane. Equivalent loading of each sample was confirmed with anti-actin. Anti-glutamine synthetase was used at a dilution of 1:10,000. After incubating with the primary antibody for 24 h at 4 C, filters were washed and incubated for 1 h at 4 C with peroxidase-conjugated anti-goat immunoglobulin (IgG) at a dilution of 1:5000. The chemiluminescence signal was detected using an ECL kit from Amersham and evaluated in the luminescence image analyzer (Image Quant LAS4000 from GE). The luminescence signal differences were analyzed using ImageJ software.
BDNF
Homogenates of hippocampal slices from controls and ureasetreated rats were assayed using the ChemiKine Brain Derived Neurotrophic Factor Sandwich ELISA (Millipore). All procedures were carried out according to the manufacturer's protocol.
Astrocyte cell cultures
Primary astrocyte cultures from Wistar rats were prepared as previously described (Gottfried et al., 2002) . Procedures were carried out in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the local authorities. Briefly, cerebral cortices of newborn Wistar rats (1-2 days old) were removed and mechanically dissociated in Ca 2+ -and Mg 2 + -free balanced salt solution, pH 7.4, containing (in mM): 137 NaCl; 5.36 KCl; 0.27 Na 2 HPO 4 ; 1.1 KH 2 PO 4 and 6.1 glucose. The cortices were cleaned of meninges and mechanically dissociated by sequential passages through a Pasteur pipette. After centrifugation at 1400 rpm for 5 min the pellet was resuspended in DMEM (pH 7.6) supplemented with 8.39 mM HEPES, 23.8 mM NaHCO3, 0.1% amphotericin, 0.032% gentamicin and 10% fetal calf serum (FCS).
Cultures were maintained in DMEM containing 10% FCS in 5% CO 2 / 95% air at 37 C, allowed to grow to confluence, and used at 21 days in vitro. Cells were incubated with or without NH 4 Cl at 5 mM for 24 h. Afterwards, media was collected for S100B and BDNF analysis.
Protein determination
Protein content was measured by Lowry's method, modified byPeterson, using bovine serum albumin as standard (Peterson,1977) .
Statistical analysis
Parametric data are reported as means AE standard errors and were analyzed by Student's t test (when two groups were considered) or by one-way analysis of variance (ANOVA) followed by Duncan's test, using SPSS-16.0. Tests are specified in the legends, with the level of significance set at p < 0.05.
Results
Urease-treated rats present hyperammonemia without hepatic dysfunction
In order to evaluate the commitment of the hippocampal structure to hyperammonemic conditions, we injected urease, i.p., to catalyze the hydrolysis of urea into carbon dioxide and ammonia. After four days of administration, urease-induced hyperammonemia (UIH) rats showed a significant elevation in serum ammonia concentration, when compared to control rats at 24 h after the last injection (Fig. 1) . On the other hand, no changes in serum transaminase activities (ALT and AST) were observed ( Table 1 ), suggesting that these animals did not develop hepatic impairment. Therefore, this animal model presented a specific ammonia elevation, rather than hepatic dysfunction. Fig. 1 . Urease induced hyperammonemia (UIH) in rats. Rats were daily injected (i.p.) with urease (UIH) (33 U/kg) for 4 days. Blood samples were collected by intracardic puncture 24 h after the last injection and ammonia levels were measured in serum by a commercial kit. Each value is the mean (AE standard error) of 5 independent rats per group. Statistical analysis was performed by Student's t test. 
UIH rats showed astrocytic dysfunction and a reduction in BDNF content in the hippocampus
UIH was able to alter astrocytic activity in the hippocampus, as demonstrated by a 47% reduction in glutamate uptake, which represents a vital function performed by astrocytes (p = 0.003; Fig. 2A) . A 54% reduction in glutamine synthetase activity, primarily responsible for the clearing of glutamate and ammonia in CNS, was also observed (p = 0.038; Fig. 2B) ; this reduction in GS activity observed was not related to any alteration in GS immunocontent (control, 1.26 AE 0.15; urease, 1.25 AE 0.8; p = 0.71; Fig. 2B, insert) . Furthermore, a dramatic reduction of 60% in GSH intracellular content was observed in hippocampi of the UIHtreated rats (p = 0.001; Fig. 2C ).
UIH also reduced the immunocontent of BDNF, an important biomarker for neurocognitive deficits. This neurotrophic factor was reduced by 31% in the hippocampus of hyperammonemic rats (p = 0.003; Fig. 3A) ; in contrast, classical markers of astrocytes, S100B and GFAP were not altered in UIH-treated animals (S100B: p = 0.37, Fig. 3B ; GFAP: controls 6.3 AE 0.7 and urease 6.0 AE 0.6 ng/mg protein; p = 0.86), indicating no sign of astrogliosis. Since serum levels of S100B have been proposed as a marker of cerebral damage in HE patients (Saleh et al., 2007; Wiltfang et al., 1999) , we wondered if ammonia per se could induce and augment of S100B in serum and CSF. Interestingly, no significant changes were observed in S100B serum (p = 0.86; Fig. 4B ), but a tendency toward increased levels was observed in the CSF (p = 0.07; Fig. 4A ) of UIH rats.
Ammonia exposure modulates BDNF and S100B release in cell cultures, as well as astrocytic function in hippocampal slices
To further investigate the involvement of S100B and BDNF in exposure to toxic ammonia concentrations, and the direct involvement of astrocytes in this response, we treated astrocyte cultures with 5 mM ammonia chloride. BDNF levels were reduced in the supernatant of astrocytes culture exposed to ammonia (Fig. 5A) . Conversely, S100B secretion was increased after 24 h of ammonia exposure (Fig. 5B) . Fig. 4 . Hyperammonemia does not change levels of S100B in the cerebrospinal fluid (CSF) and serum. Rats were injected daily (i.p.) with urease (33 U/kg) for 4 days. At 24 h after the last injection, S100B was measured in (A) CSF and (B) serum. Each value is the mean (AE standard error) from 5 rats per group. Statistical analysis was performed by Student's t test. Fig. 3 . UIH alters BDNF but not S100B in the hippocampus. Rats were injected daily (i.p.) with urease (UIH) (33 U/kg) for 4 days. At 24 h after the last injection, (A) BDNF and (B) S100B were measured in hippocampus homogenates. Each value is the mean (AE standard error) of 5 rats per group. Statistical analysis was performed by Student's t test, * indicates p < 0.05. Fig. 5 . Ammonia reduces BDNF extracellular content and increases S100B secretion in cultured astrocyte cells. Confluent astrocytes were exposed to ammonia (5 mM). After 24 h of treatment, supernatants were collected for determination of BDNF (A) and S100B (B). Each value is the mean (AE standard error) from 5 experiments. Statistical analysis was performed by Student's t test, * indicates p < 0.05.
To look at the direct effect of ammonia exposure on the hippocampus we used an acute slice preparation, previously characterized in our laboratory (Nardin et al., 2009) . This brain slice model preserves the astrocyte metabolism, cell architecture and integrative responses between cells, therefore, preserving gap junction communication (Nagy and Li, 2000) and neuronal circuitry Sajikumar et al., 2005) . Astrocytic activities were measured after 1 h of ammonia incubation at different concentrations (0.1-5 mM). Ammonia exposure did not affect slice viability even at the highest concentration (5 mM), as assessed by LDH release, neutral red incorporation and MTT reduction (Table 2 ). These results indicate that cells were still viable for the analysis of astrocytic function after ammonia exposure.
Acute exposure to ammonia also led to a significant reduction in glutamate uptake in hippocampus slices (Fig. 6A) . However, GS activity was not altered in this acute model of ammonia toxicity (Fig. 6C) , although a reduction in the GSH tripeptide was found after ammonia exposure at concentrations from 0.1 to 5 mM (Fig. 6B) , confirming a compromised redox balance in the hippocampus. We did not observe any effect of ammonia on S100B secretion or BDNF content under this experimental condition ( Fig. 6D and E) .
Discussion
Hyperammonemia compromises glutamate metabolism in the hippocampus of rats
Astrocytes are highly heterogeneous in morphology and in gene expression (Sofroniew and Vinters, 2010) . However, the effects of high levels of ammonia on astrocyte activities have been mainly studied in the cerebral cortex or in total brain extracts in animal models of HE, with a generalization of these effects to total brain functionality. Recent studies (Hiba et al., 2016; Kosenko et al., 2014a Kosenko et al., , 2014b have shown that different brain regions respond differently under conditions of hyperammonemia. GFAP expression, enzymes involved in ammonia and glutamate metabolism, as well as enzymes related to the antioxidant system are affected differently by hyperammonemia, depending on the brain region. In this study, we investigated the effect of ammonia on astrocytic activity in the hippocampus, as this is an area that is important for the cognitive deficit and depression observed in HE (Hernández-Rabaza et al., 2016) and is one of the first regions to be altered by neurocognitive disease (Moodley and Chan, 2014) .
Impairment of glutamate uptake in cultured astrocytes that have been acutely exposed to ammonia has been reported (Bender and Norenberg, 1996; Chan and Butterworth, 2003; Jayakumar et al., 2006; Kelly et al., 2009) . Reduced glutamate uptake and glutamate transporter expression has been described in the cerebral cortex of animal models of HE (Chan and Butterworth, 1999; Norenberg et al., 1997; Rose, 2002; Schmidt et al., 1990; Vaquero and Butterworth, 2006) and these effects were attributed to ammonia. We herein found, for the first time to our knowledge, that astrocyte glutamate uptake was reduced in hipocampus of UIH rats, indicating that the effect previously observed in HE is due to ammonia elevation and not necessarily due to the release of other toxins derived from liver injury. Glutamate uptake impairment by ammonia may be due to loss of expression of the glutamate transporter (Butterworth, 2002) ; however, ammonia may also rapidly alter glutamate uptake, as short exposures of our Fig. 6 . Ammonia compromises astrocyte function in hippocampal slices. Hippocampal slices from Wistar rats were exposed to ammonia (from 0.1 to 5 mM) and the following were determined after 1 h of treatment: (A) glutamate uptake; (B) GSH content; (C) GS activity; (D) BDNF content and (E) S100B secretion. Each value is the mean (AE standard error) of at least five independent experiments performed in triplicate. Means indicated by different letters are significantly different (one-way ANOVA followed by Duncan's test, with a significance level of p < 0.05). After a metabolic recovery period, hippocampal slices from Wistar rats were exposed to ammonia (5 mM) and incubated with MTT or neutral red (NR). For cell integrity evaluation, the medium was collected and extracellular LDH activity was measured after 1 h of treatment of hippocampal slices with 5 mM ammonium chloride. Each value is the mean (AE standard error) of at least 5 independent experiments performed in triplicate. Statistical analysis was performed by the Student's t test.
ex vivo model to ammonia were also found to induce reduced glutamate uptake, similar to observations in hippocampal slices incubated with serum or CSF from HE patients (Schmidt et al., 1990) . Altered pH (Kelly et al., 2009) or the augmented oxidative stress induced by ammonia may damage glutamate transporters (Trotti et al., 1998) ; similarly, increased extracellular glutamate may induce elevate reactive oxygen species (ROS) through super activation of NMDA receptors (Butterworth, 2002; Michalak et al., 1996) , corroborating our data that demonstrates an increase in the consumption of the antioxidant, GSH, in the hippocampi of these rats. Glutamine synthetase is the most important pathway for ammonia detoxification and astrocytes are the most abundant cells that express this enzyme (Montana et al., 2014) . Few studies have shown alterations in GS activity in the hippocampus due to ammonia toxicity (Girard and Butterworth, 1992; Kosenko et al., 2014a) . In fact, our in vivo model of hyperammonemia displayed reduced GS activity, but no alteration in GS expression, as previously reported in rats and patients with hepatic dysfunction in total brain extracts or cerebral cortex (Cooper and Lai, 1987; Lavoie et al., 1987) . This result is consistent with the finding of reduced GS activity in glutamatergic areas of the brain, such as the hippocampus. The reduction in GS activity associated with hyperammonia could be due to an excessive production of nitric oxide, as a result of hyperstimulation of the NMDA receptor, leading to GS nitration/inactivation (Butterworth, 2014; Kosenko et al., 2003; Schliess et al., 2002) .
We also found a significant decrease in GSH content in the hippocampus of UIH rats and in hippocampal slices following acute exposure to ammonia, consistent with the reduction in GSH/GSSG ratio observed in the total brain extract of hyperammonemic rats (Kosenko et al., 1999) . In fact, increases in reactive oxygen species (ROS) have been observed in cultured astrocytes exposed to high concentrations of ammonia (Murthy et al., 2001; Norenberg et al., 2007) and in rat brains with acute and chronic liver dysfunction (Bemeur et al., 2010) . Nevertheless, some studies have shown inconsistent results in GSH content (Murthy et al., 2000; Viegas et al., 2012; Wegrzynowicz et al., 2007) . This variation may be due to differences in the susceptibility of different brain areas (Singh et al., 2008) . Thus, we demonstrate herein that the hippocampus is sensitive to the oxidative effects produced by ammonia. Our ex vivo results shown that ammonia induced oxidative damage even during short-term exposure. This GSH reduction could be explained by an augmented consumption, due to an increase in oxidative stress induced by glutamate excitotoxicity (Atlante et al., 2001) , or even by a reduction in the substrate glutamate, which is taken up less by astrocytes (Fig. 7) .
4.2. Ammonia toxicity is able to modulate BDNF and S100B in vivo and in vitro BDNF is a neurotrophic factor that has been extensively associated with memory dysfunction, modulating short and long-term memory (Alonso et al., 2002; Yamada and Nabeshima, 2003) . A decrease in BDNF levels is observed in brain diseases, such as schizophrenia (Ahmed et al., 2015) , Alzheimer disease (Budni et al., 2015) and depression (Lee and Kim, 2010) . However, an association between hyperammonemia and HE, which exhibit cognitive deficit and depression symptoms, with BDNF content has not been made before. For the first time, we show that ammonia directly reduces the BDNF content in the hippocampus of ureasetreated rats. BDNF is produced mainly by neurons, but it has been shown that astrocytes can also secrete this neurotrophic factor in vitro (Toyomoto et al., 2005) and in vivo (Lessmann and Brigadski, 2009 ). Furthermore, BDNF may be secreted in its precursor form of pro-BDNF and uptaken by astrocytes in the extracellular space and recycled back into its mature form (Bergami et al., 2008) . Therefore, a reduction in BDNF content could indicate alterations in BDNF production/secretion by neurons or even an impairment in its recycling from astrocytes. Accordingly, we observed a reduction in BDNF secretion in cultured astrocytes exposed to ammonia, indicating that these cells play an important role in BDNF metabolism during ammonia toxicity (Fig. 7) . Furthermore, astrocytes are very important for the communication of the neuronal network, thus a reduction in BDNF secretion may interfere in neuronal activity contributing to the impairment in memory function present in HE patients.
Altered serum S100B has been reported in a number of neurodegenerative diseases (Chong et al., 2016) and in hepatic diseases, such as cirrhosis, acute liver dysfunction and hepatic encephalopathy (Bélanger et al., 2002; Desjardins et al., 2001; Isobe-Harima et al., 2008; Ribeiro et al., 2007; Saleh et al., 2007) . Although ammonia elevation has been associated with these conditions, few studies have looked at the direct effect of ammonia on S100B secretion and expression in the CNS (Bobermin et al., 2016; Leite et al., 2006) . Our results show that UIH rats did not alter S100B content either in the CSF or in the serum, although there was a trend toward an alteration in CSF. Importantly, S100B content in the CSF may reflect the total secretion of the whole brain, mitigating the effect of ammonia in isolated areas. In fact, chronic treatment with ammonia in astrocyte cultures increased the levels of S100B (Fig. 7) , as previously reported (Leite et al., 2006) . Our data indicate that chronic and direct exposure to ammonia induces alterations in S100B levels; whether the hippocampus participates in this response needs to be further investigated. Other toxins released during hepatic dysfunction, and not only ammonia, may contribute to increase levels of S100B in the serum of patients and in the animal model of HE (Isobe-Harima et al., 2008; Saleh et al., Fig. 7 . Proposed scheme for astroglial alterations induced by hyperammonemia in hippocampus. Hyperammonemia induced a reduction of glutamate uptake (1), which may explain de decrease in GS activity (2). A reduction in glutamate content may also interfere in the production of the tripeptide GSH (3). Less production of this antioxidant may increase oxidative species, which in turn may compromise glutamate transporters and GS activity due to an oxidative damage, in positive feedback way. Hippocampus of UIH rats showed reduced content of BDNF (4), corresponding with reduced secretion of BDNF in astrocytes treated with ammonia (5). Astroglial cells treated with ammonia also showed an increase in S100B secretion (6).
2007). The observed increase in levels of S100B in the CSF of hyperammonemic rats did not correlate with levels in the serum, as observed with other stimuli, such as LPS (Guerra et al., 2011) , indicating that this protein may not be the best marker for brain damage. Furthermore, acute exposure to ammonia did not affect S100B secretion or BDNF content in hippocampal slices ( Fig. 6D and E), indicating that time of ammonia exposure may be critical for these effects.
Similarly, S100B immunocontent in the hippocampus was not altered in urease-treated rats. Correspondingly, other studies found no alteration in S100B expression in the frontal cortex of rats with acute liver dysfunction (Bélanger et al., 2002; Desjardins et al., 2001) . Notably, there is not always an association between the expression and secretion of this protein (Gonçalves et al., 2008) .
GFAP, a protein characteristic of astrocytes, was not altered in urease-treated rats, showing that ammonia did not induce hippocampal astrogliosis in this structure. Furthermore, GFAP was also unchanged in the cerebellum of cirrhotic patients (Kril et al., 1997) and even a reduction in GFAP expression was assessed in a rat model of acute liver failure (Bélanger et al., 2002) . Therefore, based on these results, regions other than the hippocampus may contribute to the loss of GFAP that has been previously reported in the hyperammonemic condition.
Conclusions
We used urease administration to induce hyperammonemia without hepatic damage. The hyperammonemic condition induced alterations in important astrocytic functions. A reduction in GS activity and the deficiency in glutamate uptake may impair the classical glutamine-glutamate cycle, interfering in excitatory neurotransmission. A reduction in antioxidant capacity, as shown by reduced GSH levels, may be due to excessive GSH consumption because of an increased in oxidative stress, and/or a reduction in the GSH subtract, glutamate. The neurotrophic factor, BDNF, is also affected by ammonia toxicity and astrocytes play a specific role in BDNF reduction. These changes in BDNF levels may be involved in the cognitive deficits presented by HE patients. All these alterations were studied specifically in the hippocampus, which was found to be a region susceptible to ammonia toxicity. In our hyperammonemic model, the S100B protein was not altered in the serum, and therefore caution should be taken when considering this protein to be a good marker for HE disease. The Hippocampus presents vulnerability to ammonia toxicity, particularly presenting reduced glutamate uptake activity and BDNF content; these findings contribute to the understanding of the neuropsychiatric alterations in HE.
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